首页> 美国卫生研究院文献>BMC Pharmacology Toxicology >An inhibitor of 11-β hydroxysteroid dehydrogenase type 1 (PF915275) alleviates nonylphenol-induced hyperadrenalism and adiposity in rat and human cells
【2h】

An inhibitor of 11-β hydroxysteroid dehydrogenase type 1 (PF915275) alleviates nonylphenol-induced hyperadrenalism and adiposity in rat and human cells

机译:11-β羟类固醇脱氢酶1型抑制剂(PF915275)减轻壬基酚引起的大鼠和人类细胞肾上腺皮质功能亢进和肥胖

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundNonylphenol (NP) is an environmental endocrine-disrupting chemical (EDC) detected in human cord blood and milk. NP exposure in developmental periods results in hyperadrenalism and increasing 11β-hydroxysteroid dehydrogenase I (11β-HSD1) activity in an adult rat model. Alleviating 11β-HSD1 activity is therefore a logical and common way to treat hyperadrenalism. PF915275 (PF; 4′-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide) is a selective inhibitor for 11β-HSD1. This study aimed to determine whether PF915275 could alleviate the hyperadrenalism induced by NP. In addition to a rat model, the effects of NP and PF915275 were measured in human preadipocytes.
机译:背景壬基酚(NP)是一种在人脐带血和牛奶中检测到的破坏环境内分泌的化学物质(EDC)。在成年大鼠模型中,NP暴露于发育期会导致肾上腺皮质功能亢进和11β-羟类固醇脱氢酶I(11β-HSD1)活性增加。因此,减轻11β-HSD1活性是治疗肾上腺皮质功能亢进症的合乎逻辑的通用方法。 PF915275(PF; 4'-氰基-联苯-4-磺酸(6-氨基-吡啶-2-基)-酰胺)是11β-HSD1的选择性抑制剂。这项研究旨在确定PF915275是否可以缓解NP引起的肾上腺皮质功能亢进。除大鼠模型外,还在人前脂肪细胞中测量了NP和PF915275的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号